Ivan Hyep Sells 12,500 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 12,500 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $27.97, for a total value of $349,625.00. Following the completion of the transaction, the chief financial officer owned 129,855 shares of the company’s stock, valued at $3,632,044.35. The trade was a 8.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Wednesday, July 8th, Ivan Hyep sold 28,000 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.85, for a total value of $807,800.00.
• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.42, for a total value of $187,864.00.

Bicara Therapeutics Stock Down 4.1%

Shares of Bicara Therapeutics stock opened at $23.63 on Friday. Bicara Therapeutics Inc. has a 52 week low of $10.30 and a 52 week high of $30.99. The business’s fifty day simple moving average is $26.06 and its 200-day simple moving average is $21.79. The firm has a market cap of $1.56 billion, a PE ratio of -7.62 and a beta of -0.75.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.82). As a group, equities analysts expect that Bicara Therapeutics Inc. will post -3.5 earnings per share for the current year.

Institutional Trading of Bicara Therapeutics

Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Bicara Therapeutics in the second quarter valued at approximately $114,250,000. T. Rowe Price Investment Management Inc. lifted its holdings in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after buying an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in Bicara Therapeutics during the 4th quarter worth approximately $44,484,000. Vestal Point Capital LP boosted its position in Bicara Therapeutics by 80.6% in the 2nd quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock valued at $46,450,000 after buying an additional 2,231,025 shares during the period. Finally, Franklin Resources Inc. acquired a new position in shares of Bicara Therapeutics in the fourth quarter worth $27,265,000.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Management said enrollment for the pivotal study of ficerafusp alfa remains on track for 2026. Progress toward this milestone could provide an important catalyst for the clinical-stage biotechnology company. Bicara Therapeutics cancer study remains on track
• Positive Sentiment: Analysts raised several price targets following the quarterly results. BTIG increased its target from $28 to $39 and retained a Buy rating, while Morgan Stanley raised its target to $39 with an Overweight rating. The reported consensus view remains Moderately Buy-rated, with an average target near $32.73. Analysts raise Bicara forecasts
• Neutral Sentiment: Bicara reported a second-quarter loss of $0.82 per share, matching the consensus estimate. The result did not provide a major earnings surprise, leaving clinical execution and upcoming trial milestones as the primary valuation drivers. Bicara Q2 2026 earnings call transcript
• Neutral Sentiment: Wells Fargo raised its price target from $16 to $23 but maintained an Equal Weight rating, highlighting disagreement among analysts about the stock’s risk-reward profile. A reported leadership shake-up also introduces some execution uncertainty as Bicara advances its development programs. Bicara leadership and milestone timeline
• Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep sold a combined 41,250 shares for approximately $1.15 million. The sales were made under pre-arranged Rule 10b5-1 plans, and the executives retained substantial holdings, but the cluster of insider sales can still pressure sentiment.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Wedbush lifted their price target on shares of Bicara Therapeutics from $30.00 to $33.00 and gave the company an “outperform” rating in a research report on Wednesday. BTIG Research upped their price objective on shares of Bicara Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a research report on Wednesday, May 27th. Guggenheim assumed coverage on shares of Bicara Therapeutics in a report on Monday, May 11th. They issued a “buy” rating and a $42.00 target price for the company. Finally, Mizuho boosted their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.73.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.